Corporate News Update – Dimerix Limited (DXB.AX)
Stock Performance Snapshot
- Current price: AUD 0.20
- 24‑hour movement: –2.38 % (closing at 11:26 PM Central Europe, Friday 23 Nov)
- Trading volume (last 24 h): AUD 61.6 k
- Market capitalisation: AUD 85.2 mn
- Shares outstanding: 600.4 million
- 52‑week high: AUD 0.66 (23 Dec 2025)
- 52‑week low: AUD 0.16 (11 Jun 2026)
- 200‑day simple moving average: AUD 0.30
- Year‑to‑date change (since last month’s close): –12.77 %
Upcoming Annual General Meeting
Dimerix Limited will convene its annual general meeting on 20 November 2026. The agenda, prepared in accordance with ASX listing requirements, will address the following key items:
- Presentation of Financial Statements
- Results for the year ended 30 June 2026 will be laid out in detail, followed by a discussion of performance metrics and forward guidance.
- Remuneration Report
- A non‑binding resolution will seek shareholders’ approval for the remuneration report, underscoring transparency and alignment with long‑term value creation.
- Director Re‑elections
- Dr James Williams and Mr Paul House will be nominated for re‑election as directors, a move the board believes sustains governance stability and strategic continuity.
- Incentive‑Related Resolutions
- Director Shares for Mr David Morris: A proposal to issue shares in lieu of a short‑term cash incentive.
- Sign‑On Rights: The allocation of sign‑on rights to key personnel.
- Long‑Term Incentive Performance Rights: Granting of performance‑linked rights, intended to align executive interests with shareholder returns.
- Placement Capacity Expansion
- A special resolution will increase the company’s placement capacity by an additional 10 %. This amendment will enable future equity issuances without requiring a separate shareholder vote, thereby enhancing capital‑raising flexibility.
The board has conveyed confidence that these measures reinforce Dimerix’s strategic objectives, support shareholder interests, and strengthen the company’s governance framework.
Context from Peer Movements
In the past 24 hours, several Australian equities have exhibited notable shifts:
| Symbol | Current Price | 24‑h % | Market Cap (mn AUD) | Additional Notes |
|---|---|---|---|---|
| Adisyn (AI1.AX) | 0.08 | –3.61 % | 97.7 | Decline in valuation |
| Emvision Medical Devices (EMV.AX) | 1.46 | –3.48 % | 99.3 | Appointment of non‑executive director Carmel Monaghan; performance‑rights grant pending |
| Brisbane Broncos (BBL.AX) | 1.45 | +1.03 % | 96.1 | Slight upside |
| Baby Bunting (BBN.AX) | 1.01 | –3.37 % | 96.2 | Decline in share price |
| Island (ILA.AX) | 0.33 | –5.88 % | 100.7 | Significant drop |
These movements provide a broader market backdrop against which Dimerix’s own price action should be interpreted. The decline in peer valuations, coupled with Dimerix’s own downward trajectory, may reflect sector‑specific pressures or broader investor sentiment toward biotech equities in Australia.
About Dimerix Limited
Dimerix Limited is a biotechnology enterprise headquartered in Fitzroy, Australia. The company focuses on the development and commercialization of therapeutic agents for chronic kidney disease, a growing health challenge. In addition to its product pipeline, Dimerix conducts clinical trials to support efficacy and safety data generation. For further details, the company’s website (www.dimerix.com ) offers comprehensive information on its research activities, corporate governance, and investor relations.
